HK inno.N

What HK inno.N does

HK inno.N is a South Korean KOSDAQ-listed (195940) pharmaceutical and bio-health company headquartered in Cheongju-si, operating as the pharmaceutical and health subsidiary of Kolmar Group — a conglomerate that surpassed 5 trillion KRW in total assets and was designated a large business group by Korea's Fair Trade Commission in April 2026. The company runs three integrated business segments: prescription medicines (K-CAB, Korea's #1 peptic ulcer drug and 30th novel drug; Lovajet for hypercholesterolemia; saline solutions; an amlodipine/valsartan/rosuvastatin combination hypertension treatment), health consumer products (Condition hangover cure, exported to 15+ countries with #1 share in China, Vietnam, and Mongolia; Hutgaesoo beverages; Saessagbori barley grass), and beauty/skincare (bewants slow-aging brand, Scalpmed scalp care, Klederma dermatology products).

The company's technology portfolio centers on pharmaceutical R&D across digestive diseases, oncology, immunological conditions, and a GLP-1 obesity pipeline (including Korean rights to ecnoglutide via Hangzhou Sciwind Biosciences and proprietary candidates showing superiority over semaglutide in head-to-head trials as of June 2026), plus a JAK-1 inhibitor pet atopy drug that completed Phase 3 as the only approved therapy of its kind in Korea. R&D infrastructure spans new drug discovery, biotechnology including vaccines and cell/gene therapies, and Health&Beauty formulation labs.

HK inno.N's go-to-market is multi-channel: prescription drugs flow through Korean healthcare providers, hospitals, and pharmacies; health products sell direct-to-consumer via the proprietary innonmall.com e-commerce platform and export through international distributors; beauty products distribute through Olive Young retail in Korea and now the US (Pasadena store plus online), augmented by B2B partnerships such as the Weepun 'Office Popup' channel. Revenue is generated primarily through one-time product sales across all three segments, with the prescription-drug portfolio crossing 1 trillion KRW for the first time in 2025 and Q1 2025 operating profit growing 30.8% year-on-year. The company employs 1,001-5,000 people and is led by CEO Seokhee Kang.

Name

HK inno.N

Legal name

에이치케이이노엔(주)

Website

https://inno-n.com

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

HK inno.N is a South Korean KOSDAQ-listed pharmaceutical and bio-health company (Kolmar Group subsidiary) developing and selling prescription drugs (K-CAB for peptic ulcers, GLP-1 obesity candidates), consumer health products (Condition hangover cure exported to 15+ countries), and beauty/skincare brands (bewants) across Korea, Asia, and the US.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

Keywords

• Pharmaceutical manufacturing
• Prescription drugs
• Health beverages
• Skincare products
• Novel drug development

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: HK inno.N generates significant revenue from prescription drugs, including K-CAB for gastrointestinal conditions. The prescription-drug portfolio exceeded 1 trillion won in revenue for the first time.
2. Health Consumer Products: Health and functional beverages including Condition (hangover cure), Hutgaesoo (beverage), and health functional foods sold in Korea and exported to 15+ countries.
3. Beauty / Cosmetics: Beauty products under brands such as bewants (비원츠), Scalpmed, Klederma sold through retail and e-commerce channels in Korea and internationally.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

HK inno.N manufactures and sells prescription pharmaceuticals (including the novel P-CAB peptic ulcer drug K-CAB, Lovajet for cholesterol, X1 Combination for hypertension, and saline injections), health beverages (Condition hangover cure, Hutgaesoo, Saessagbori, Tealog), and beauty/skincare products (Bewants, Scalpmed, Klederma). The company also conducts novel drug R&D across digestive, cancer, immune, and metabolic diseases, and offers CMO/OEM contract manufacturing through Kolmar Group infrastructure.

Product overview

HK inno.N is a global bio-health company operating across three main business divisions: prescription medicines (전문의약품), health products (HEALTH), and beauty products (BEAUTY). The prescription medicines segment includes major drugs like K-CAB (the top-selling gastric ulcer medication in Korea and the country's 30th novel drug), saline solutions, and cardiovascular treatments. The health segment features Condition, a hangover recovery drink with proven clinical efficacy and dominant market share in China, Vietnam, and Mongolia. The beauty segment includes Bewants, a slow-aging skincare brand targeting MZ generation consumers with peptide and PDRN-based products. The company also operates in R&D focusing on new drug development for digestive, cancer, and immunological diseases, as well as biotechnology including vaccines and cell/gene therapies. The company is part of Kolmar Group and operates from its headquarters in Cheongju, Korea.

Differentiator

Problem solved

Functional benefit

Brands

• Condition: Hangover relief drink with proven hangover improvement effects through human application testing. Exported to over 15 countries and holds top market share in China, Vietnam, and Mongolia.
• bewants
• K-CAB
• 헛개수
• 새싹보리
• 티로그
• 스칼프메드
• 클레더마

Products and services

• K-CAB (케이캡정) Prescription pharmaceutical - potassium-competitive acid blocker (P-CAB) for the treatment of peptic (gastric/duodenal) ulcers. Sold to hospitals, clinics, and pharmacies via the prescription drug channel. K-CAB is Korea's 30th homegrown novel drug and the leading P-CAB in Korea's gastric ulcer market.
• Lovajet (로바젯정) Prescription pharmaceutical for cholesterol management (statin class). Sold through hospitals, clinics, and pharmacies for patients with hypercholesterolemia and related cardiovascular risk.
• X1 Combination (엑스원알정) Prescription combination drug for hypertension treatment. Sold through hospitals and pharmacies for blood pressure management.
• HK inno.N 0.9% Saline Injection (이노엔0.9%생리식염주사액) Basic 0.9% sodium chloride physiological saline injection for IV fluid therapy, rehydration, and clinical use. Sold to hospitals and clinics as a fundamental IV solution.
• Condition (컨디션) Hangover cure functional beverage marketed to adult consumers. Leading hangover brand in China, Vietnam, and Mongolia; sold through retail, e-commerce (innonmall.com), and international distributors across 14 countries.
• Hutgaesoo (헛개수) Thirst-quenching functional beverage (Hovenia dulcis-based) sold to consumers via retail and e-commerce channels.
• Saessagbori (새싹보리) Health-oriented barley-based beverage targeting health-conscious consumers; sold through retail and e-commerce.
• Tealog (티로그) Tea-based health/beauty beverage positioned at the intersection of functional drinks and beauty-from-within products. Sold via retail and e-commerce.
• Bewants (비원츠) Dermo-cosmetic skincare brand featuring seaweed-derived PDRN ingredients. Includes Sun Stick (Skin Fit Essence Sebum Control), Jelly Mask (Seaweed PDRN Glow Peel Off), and Eye Serum Stick (Peptide X Firming). Sold via innonmall.com and Olive Young retail in Korea and the US.
• Scalpmed (스칼프메드) Scalp care skincare brand targeting scalp health and hair-related concerns; sold through retail and e-commerce channels.
• Klederma (클레더마) Dermatology-focused skincare brand offering products positioned for clinical/skin-condition-related care; sold through retail and e-commerce.
• CMO/OEM Contract Manufacturing Contract manufacturing services for pharmaceutical and health/beauty products leveraging Kolmar Group's manufacturing infrastructure. Sold to third-party brand owners seeking production capacity.

Quantifiable outcome

• HK inno.N prescription-drug portfolio exceeded 1 trillion won in revenue for the first time.
• +1 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered minor and core.

• WeepunminorGTM or Marketing Partner · 26 March 2026Weepun, a BaaS (Business as a Service) platform company, launched the 'Office Popup' marketing model with HK Innoen's Condition brand, targeting employees at major corporate offices including Moloco, OK Savings Bank, Hanwha Hotels & Resorts, and YTN, attracting 5,711 participants. Weepun plans to develop this B2B office marketing channel into a media solution driving consumption conversion.
• Hangzhou Sciwind BiosciencescoreStrategic or Co-development PartnerHK inno.N holds Korean rights to ecnoglutide, a new GLP-1 obesity drug developed by Hangzhou Sciwind Biosciences, which received NMPA approval in China. Pfizer's Chinese subsidiary acquired China sales rights for ecnoglutide. Multiple Korean pharmaceutical companies including HK inno.N are developing competing GLP-1 obesity treatments.
• Kolmar GroupcoreOthersHK inno.N is an affiliate of Kolmar Group, Korea's first cosmetics ODM designated as a large business group by the Fair Trade Commission. Kolmar Group surpassed 5 trillion won in total assets and has diversified from cosmetics into pharmaceuticals, biotechnology, and functional health foods. HK inno.N contributes to the group's pharmaceutical growth alongside Kolmar Korea and Kolmar BNH.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Yuhan Corporation: Yuhan is one of Korea's largest pharmaceutical companies with a similar diversified model spanning branded prescription drugs (respiratory, GI, oncology) and consumer health products. Comparable in scale, Korean market focus, and listed on KRX, making it the most directly comparable Korean pharma peer to HK inno.N.
• Hanmi Pharmaceutical: Hanmi is a Korean specialty pharmaceutical company focused on innovative drug development across diabetes, oncology, and autoimmune diseases with strong global licensing deals. Highly comparable to HK inno.N's specialty pharma ambitions and GLP-1 obesity pipeline positioning.
• Daewoong Pharmaceutical: Daewoong is a major Korean pharmaceutical manufacturer with branded prescription drugs (Botulax, Nabota) and OTC/health consumer products including beverages. Comparable business mix of branded pharma + consumer health, similar Korean market positioning, and similar diversification strategy.
• Dong-A ST: Dong-A ST is a Korean pharmaceutical company with branded prescription products (Stillen, Motilitone) and a growing consumer health portfolio. Comparable mid-to-large Korean pharma with both prescription and consumer health exposure.
• JW Pharmaceutical: JW Pharmaceutical is a Korean pharmaceutical company with prescription drugs (especially in women's health and GI) and consumer health products. Mid-tier Korean pharma with similar business model of branded Rx + OTC consumer products.

Broad incumbents

• Celltrion: Celltrion is one of Korea's largest biopharma companies specializing in biosimilars (Remsima, globally top-selling biosimilar). Comparable as a major Korean listed pharma with global ambitions, though more focused on biologics/biosimilars vs HK inno.N's small molecule + consumer health mix.
• GC Biopharma: GC Biopharma (formerly Green Cross) is a major Korean biopharmaceutical company with vaccines, plasma products, and branded prescription drugs. Comparable as a major Korean listed pharma with a similar scale of operations, though more biologics-focused.
• Amorepacific: Amorepacific is Korea's largest beauty conglomerate with global brands (Sulwhasoo, Laneige, Innisfree). Relevant peer for HK inno.N's bewants beauty brand, given both target the Korean MZ generation with K-beauty products and Amorepacific has established US distribution that bewants is trying to build.
• LG Household & Health Care: LG H&H is a Korean conglomerate with cosmetics (Whoo, Su:m37°), household products, and beverages (Coca-Cola bottling in Korea). Comparable as a Korean conglomerate with health/beauty/beverage consumer products, though much larger scale and different therapeutic focus.

Others

• Kolmar Korea: Kolmar Korea is HK inno.N's parent affiliate within Kolmar Group and Korea's largest cosmetics ODM with 2.72 trillion KRW consolidated revenue. Not a direct competitor but a key sibling entity that shares corporate infrastructure and management, providing manufacturing and distribution synergies to HK inno.N.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@CH_inno.N
• LinkedInlinkedin.com/company/inno-n/posts/?feedView=all
• Instagraminstagram.com/inno.n_official

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HK inno.N